tiprankstipranks
Iterum Therapeutics Gains FDA Approval for ORLYNVAH
Company Announcements

Iterum Therapeutics Gains FDA Approval for ORLYNVAH

Don't Miss our Black Friday Offers:

The latest update is out from Iterum Therapeutics ( (ITRM) ).

Iterum Therapeutics has received FDA approval for ORLYNVAH™, an innovative oral treatment for uncomplicated urinary tract infections (uUTIs) in adult women with limited treatment options. This approval marks a significant milestone as ORLYNVAH™ offers a novel solution to combat antibiotic-resistant infections, showcasing superior efficacy in clinical trials. The company aims to leverage this approval to pursue strategic partnerships or commercialization efforts, addressing a critical need in the market for effective uUTI treatments.

For a thorough assessment of ITRM stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyIterum Therapeutics regains full Nasdaq compliance
TipRanks Auto-Generated NewsdeskIterum Therapeutics’ Strategic Advances with ORLYNVAH Approval
TheFlyIterum Therapeutics reports Q3 non-GAAP EPS (24c) vs. ($1.20) last year
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App